{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:05:34Z","timestamp":1790355934539,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T00:00:00Z","timestamp":1567123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["P30430-BBL"],"award-info":[{"award-number":["P30430-BBL"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["W1206-B05"],"award-info":[{"award-number":["W1206-B05"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["P30592-BBL"],"award-info":[{"award-number":["P30592-BBL"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.neuropharm.2019.107754","type":"journal-article","created":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T11:13:50Z","timestamp":1567163630000},"page":"107754","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Functional characterization of novel bumetanide derivatives for epilepsy treatment"],"prefix":"10.1016","volume":"162","author":[{"given":"Theresa","family":"Auer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Schreppel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Erker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6373-3717","authenticated-orcid":false,"given":"Christoph","family":"Schwarzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2019.107754_bib1","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/0306-4522(80)90049-4","article-title":"Injections of kainic acid into the amygdaloid complex of the rat: an electrographic, clinical and histological study in relation to the pathology of epilepsy","volume":"5","author":"Ben-Ari","year":"1980","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2019.107754_bib2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.neuropharm.2018.09.025","article-title":"Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti-seizure efficacy","volume":"143","author":"Brandt","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.107754_bib3","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1212\/WNL.0b013e3182563b19","article-title":"Patterns of treatment response in newly diagnosed epilepsy","volume":"78","author":"Brodie","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2019.107754_bib4","doi-asserted-by":"crossref","first-page":"e539","DOI":"10.1542\/peds.2014-4133","article-title":"Paradoxical benzodiazepine response: a rationale for bumetanide in neurodevelopmental disorders","volume":"136","author":"Bruining","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.neuropharm.2019.107754_bib5","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/epi4.12112","article-title":"Epilepsy as a dynamic disease: a Bayesian model for differentiating seizure risk from natural variability","volume":"3","author":"Chiang","year":"2018","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.neuropharm.2019.107754_bib6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fncel.2012.00055","article-title":"Molecular mechanism of circadian rhythmicity of seizures in temporal lobe epilepsy","volume":"6","author":"Cho","year":"2012","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107754_bib7","doi-asserted-by":"crossref","first-page":"339","DOI":"10.5455\/medarh.2016.70.339-341","article-title":"Brain edema after ischaemic stroke","volume":"70","author":"Dostovic","year":"2016","journal-title":"Med. Arch."},{"key":"10.1016\/j.neuropharm.2019.107754_bib8","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/ana.21229","article-title":"Bumetanide enhances phenobarbital efficacy in a neonatal seizure model","volume":"63","author":"Dzhala","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107754_bib9","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/nm1301","article-title":"NKCC1 transporter facilitates seizures in the developing brain","volume":"11","author":"Dzhala","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2019.107754_bib10","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/epi.13346","article-title":"The bumetanide prodrug BUM5, but not bumetanide, potentiates the antiseizure effect of phenobarbital in adult epileptic mice","volume":"57","author":"Erker","year":"2016","journal-title":"Epilepsia"},{"issue":"Suppl. 11","key":"10.1016\/j.neuropharm.2019.107754_bib11","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1528-1167.2005.00403.x","article-title":"Mortality of epilepsy in developed countries: a review","volume":"46","author":"Forsgren","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2019.107754_bib12","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1124\/jpet.103.059139","article-title":"Interactions of human organic anion transporters with diuretics","volume":"308","author":"Hasannejad","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.107754_bib13","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1528-1157.1996.tb00644.x","article-title":"Severe, uncontrolled hypertension and adult-onset seizures: a case-control study in Rochester, Minnesota","volume":"37","author":"Hesdorffer","year":"1996","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2019.107754_bib14","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3109\/13880209.2014.942789","article-title":"Alteration of pentylenetetrazole-induced seizure threshold by chronic administration of ginger (Zingiber officinale) extract in male mice","volume":"53","author":"Hosseini","year":"2015","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.neuropharm.2019.107754_bib15","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1161\/STROKEAHA.118.024287","article-title":"A novel Na","volume":"50","author":"Huang","year":"2019","journal-title":"Stroke"},{"key":"10.1016\/j.neuropharm.2019.107754_bib16","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.brainres.2015.03.005","article-title":"Prevention of status epilepticus-induced brain edema and neuronal cell loss by repeated treatment with high-dose levetiracetam","volume":"1608","author":"Itoh","year":"2015","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2019.107754_bib17","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1162\/neco.2007.19.3.706","article-title":"Synchrony of neuronal oscillations controlled by GABAergic reversal potentials","volume":"19","author":"Jeong","year":"2007","journal-title":"Neural Comput."},{"key":"10.1016\/j.neuropharm.2019.107754_bib18","doi-asserted-by":"crossref","first-page":"766","DOI":"10.15252\/embr.201438840","article-title":"Genetically encoded impairment of neuronal KCC2 cotransporter function in human idiopathic generalized epilepsy","volume":"15","author":"Kahle","year":"2014","journal-title":"EMBO Rep."},{"key":"10.1016\/j.neuropharm.2019.107754_bib19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1535-7597.2002.00013.x","article-title":"Diuretics as antiepileptic drugs","volume":"2","author":"Kanner","year":"2002","journal-title":"Epilepsy Curr."},{"key":"10.1016\/j.neuropharm.2019.107754_bib20","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S1474-4422(18)30335-1","article-title":"Circadian rhythm and epilepsy","volume":"17","author":"Khan","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2019.107754_bib21","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1684\/epd.2012.0524","article-title":"Epilepsy and anxiety: epidemiology, classification, aetiology, and treatment","volume":"14","author":"Kimiskidis","year":"2012","journal-title":"Epileptic Disord."},{"key":"10.1016\/j.neuropharm.2019.107754_bib22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejphar.2005.09.054","article-title":"Mouse organic anion transporter 2 and 3 (mOAT2\/3[Slc22a7\/8]) mediates the renal transport of bumetanide","volume":"524","author":"Kobayashi","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.107754_bib23","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1212\/WNL.0b013e3182a6cbeb","article-title":"Postictal generalized EEG suppression: an inconsistent finding in people with multiple seizures","volume":"81","author":"Lamberts","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2019.107754_bib24","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/brain\/awl384","article-title":"Endogenous dynorphin in epileptogenesis and epilepsy: anticonvulsant net effect via kappa opioid receptors","volume":"130","author":"Loacker","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2019.107754_bib25","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.neuropharm.2012.05.045","article-title":"Cation-chloride cotransporters NKCC1 and KCC2 as potential targets for novel antiepileptic and antiepileptogenic treatments","volume":"69","author":"L\u00f6scher","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.107754_bib26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.seizure.2016.10.015","article-title":"Long-term outcomes of surgical treatment for epilepsy in adults with regard to seizures, antiepileptic drug treatment and employment","volume":"44","author":"Malmgren","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.neuropharm.2019.107754_bib27","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.seizure.2007.05.005","article-title":"Timed pentylenetetrazol infusion test: a comparative analysis with s.c.PTZ and MES models of anticonvulsant screening in mice","volume":"16","author":"Mandhane","year":"2007","journal-title":"Seizure"},{"key":"10.1016\/j.neuropharm.2019.107754_bib28","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.neurol.2015.01.561","article-title":"Surgical treatment for mesial temporal lobe epilepsy associated with hippocampal sclerosis","volume":"171","author":"Mathon","year":"2015","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.neuropharm.2019.107754_bib29","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.seizure.2013.02.002","article-title":"Early predictors of outcome in newly diagnosed epilepsy","volume":"22","author":"Mohanraj","year":"2013","journal-title":"Seizure"},{"key":"10.1016\/j.neuropharm.2019.107754_bib30","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1152\/jn.90761.2008","article-title":"Bumetanide, an NKCC1 antagonist, does not prevent formation of epileptogenic focus but blocks epileptic focus seizures in immature rat hippocampus","volume":"101","author":"Nardou","year":"2009","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2019.107754_bib31","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/brain\/awr041","article-title":"Neuronal chloride accumulation and excitatory GABA underlie aggravation of neonatal epileptiform activities by phenobarbital","volume":"134","author":"Nardou","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2019.107754_bib32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1021\/jm00235a010","article-title":"Aminobenzoic acid diuretics. 7. 3-Substituted 4-phenyl-, 4-arylcarbonyl-, and 4-arylmethyl-5-sulfamoylbenzoic acids and related compounds","volume":"18","author":"Nielsen","year":"1975","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2019.107754_bib33","first-page":"F885","article-title":"Ultrastructural localization of Na-K-2Cl cotransporter in thick ascending limb and macula densa of rat kidney","volume":"275","author":"Nielsen","year":"1998","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.neuropharm.2019.107754_bib34","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1021\/bk-1978-0083.ch002","article-title":"Structure-activity relationships of aminobenzoic acid diuretics and related compounds (1)","author":"Nielsen","year":"1978","journal-title":"Diuretic Agents"},{"key":"10.1016\/j.neuropharm.2019.107754_bib35","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2019.107754_bib36","series-title":"The Mouse Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2001"},{"key":"10.1016\/j.neuropharm.2019.107754_bib37","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/epi.13805","article-title":"Postictal generalized EEG suppression and respiratory dysfunction following generalized tonic-clonic seizures in sleep and wakefulness","volume":"58","author":"Peng","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2019.107754_bib38","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1054-3589(10)58010-4","article-title":"GABAB receptors: physiological functions and mechanisms of diversity","volume":"58","author":"Pinard","year":"2010","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.107754_bib39","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1684\/epd.2012.0532","article-title":"Animal models of drug-resistant epilepsy","volume":"14","author":"Potschka","year":"2012","journal-title":"Epileptic Disord."},{"key":"10.1016\/j.neuropharm.2019.107754_bib40","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/epi.12620","article-title":"Pharmacotherapeutic targeting of cation-chloride cotransporters in neonatal seizures","volume":"55","author":"Puskarjov","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2019.107754_bib41","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1208\/s12248-008-9009-8","article-title":"Prodrug approaches for CNS delivery","volume":"10","author":"Rautio","year":"2008","journal-title":"AAPS J."},{"key":"10.1016\/j.neuropharm.2019.107754_bib42","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0920-1211(98)00106-5","article-title":"Clinical aspects and biological bases of drug-resistant epilepsies","volume":"34","author":"Regesta","year":"1999","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2019.107754_bib43","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0306-4522(02)00064-7","article-title":"Evolution of hippocampal epileptic activity during the development of hippocampal sclerosis in a mouse model of temporal lobe epilepsy","volume":"112","author":"Riban","year":"2002","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2019.107754_bib44","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.neuropharm.2017.02.006","article-title":"Multiple blood-brain barrier transport mechanisms limit bumetanide accumulation, and therapeutic potential, in the mammalian brain","volume":"117","author":"R\u00f6mermann","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.107754_bib45","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1524-6175.2004.03789.x","article-title":"Diuretic-related side effects: development and treatment","volume":"6","author":"Sica","year":"2004","journal-title":"J. Clin. Hypertens."},{"key":"10.1016\/j.neuropharm.2019.107754_bib46","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/epi.13270","article-title":"Bumetanide reduces seizure progression and the development of pharmacoresistant status epilepticus","volume":"57","author":"Sivakumaran","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2019.107754_bib47","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/0883073812470734","article-title":"Pharmacological treatment of neonatal seizures: a systematic review","volume":"28","author":"Slaughter","year":"2013","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.neuropharm.2019.107754_bib48","doi-asserted-by":"crossref","first-page":"8038","DOI":"10.1038\/ncomms9038","article-title":"Mutations in SLC12A5 in epilepsy of infancy with migrating focal seizures","volume":"6","author":"St\u00f6dberg","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2019.107754_bib49","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3389\/fneur.2017.00301","article-title":"Drug-resistant epilepsy: multiple hypotheses, few answers","volume":"8","author":"Tang","year":"2017","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107754_bib50","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/ana.24124","article-title":"A novel prodrug-based strategy to increase effects of bumetanide in epilepsy","volume":"75","author":"T\u00f6llner","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107754_bib51","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/ejn.12424","article-title":"Consequences of inhibition of bumetanide metabolism in rodents on brain penetration and effects of bumetanide in chronic models of epilepsy","volume":"39","author":"T\u00f6pfer","year":"2014","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107754_bib52","series-title":"Fact Sheet 999","author":"WHO","year":"2015"},{"key":"10.1016\/j.neuropharm.2019.107754_bib53","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.neuroscience.2005.07.047","article-title":"Y1-receptors regulate the expression of Y2-receptors in distinct mouse forebrain areas","volume":"136","author":"Wittmann","year":"2005","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2019.107754_bib54","article-title":"STE20\/SPS1-related proline\/alanine-rich kinase is involved in plasticity of GABA signaling function in a mouse model of acquired epilepsy","volume":"8","author":"Yang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2019.107754_bib55","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1111\/bph.13474","article-title":"The G-protein biased partial kappa opioid receptor agonist 6\u2019-GNTI blocks hippocampal paroxysmal discharges without inducing aversion","volume":"173","author":"Zangrandi","year":"2016","journal-title":"Br. J. Pharmacol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390819303132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390819303132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T01:36:26Z","timestamp":1777426586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390819303132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":55,"alternative-id":["S0028390819303132"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107754","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Functional characterization of novel bumetanide derivatives for epilepsy treatment","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107754","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107754"}}